Abstract
Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta-treated patients. We report two MS patients who developed cytomegalovirus disease within 1 month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely. Neurologists should be aware of this serious but treatable complication. andcopy; SAGE Publications.
Original language | English |
---|---|
Pages (from-to) | 874-876 |
Number of pages | 3 |
Journal | Multiple Sclerosis |
Volume | 23 |
Issue number | 6 |
DOIs | |
State | Published - May 1 2017 |
Keywords
- Multiple sclerosis
- alemtuzumab
- cytomegalovirus
- cytomegalovirus reactivation
- herpes virus
- multiple sclerosis treatment